Literature DB >> 7507733

Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas.

A Pinto1, A Gloghini, V Gattei, D Aldinucci, V Zagonel, A Carbone.   

Abstract

The product of the proto-oncogene c-kit is a transmembrane receptor protein that plays an important role in the regulation of normal and neoplastic hematopoiesis via the interaction with its specific ligand termed stem cell factor. To examine whether c-kit product is possibly involved in the pathogenesis of human lymphomas, we analyzed the expression of the c-kit protein in neoplastic cells from a variety of lymphoid tumors by immunostaining of lymph node frozen sections with the 17F11 antibody, detecting an extracellular epitope of the c-kit receptor, and of c-kit RNA by Northern blot hybridization. Of 24 nonHodgkin's lymphomas (NHL) of B- and T-cell phenotype, none expressed immunodetectable c-kit protein that was also not evidenced in lymphoid cells of reactive lymph nodes and normal tonsils. In contrast, c-kit protein was expressed by Reed-Sternberg cells and their mononuclear variants from 11 of 21 Hodgkin's disease (HD) cases, and in tumor cells from 11 of 16 cases of CD30+ anaplastic large cell lymphoma (ALCL). c-kit specific mRNA was also detected in lymph node tissues from HD and ALCL cases but not in neoplastic tissues from NHL other than ALCL. In addition, c-kit/CD30+ tumor cells were evidenced by flow cytometry in a patient displaying massive bone marrow involvement by ALCL. With the exclusion of lymphocyte predominance cases of HD that resulted c-kit expression and the other histologic subtypes of HD or the immunologic phenotype of tumor cells (B, T, nonB-nonT) in both HD and ALCL. The highly restricted expression of the c-kit product among human lymphomas to HD and ALCL provides a further biologic link between these two closely related lymphoma entities.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507733

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease.

Authors:  A Carbone; A Gloghini; H J Gruss; A Pinto
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

2.  CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.

Authors:  H J Gruss; A Pinto; A Gloghini; E Wehnes; B Wright; N Boiani; D Aldinucci; V Gattei; V Zagonel; C A Smith; M E Kadin; C von Schilling; R G Goodwin; F Herrmann; A Carbone
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

3.  BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression.

Authors:  A Carbone; G Gaidano; A Gloghini; C Pastore; G Saglio; U Tirelli; R Dalla-Favera; B Falini
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

4.  Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells.

Authors:  Donatella Aldinucci; Dalisa Poletto; Annunziata Gloghini; Paola Nanni; Massimo Degan; Tiziana Perin; Paola Ceolin; Francesca Maria Rossi; Valter Gattei; Antonino Carbone; Antonio Pinto
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

5.  Reverse transcriptase polymerase chain reaction for the Ki-1 anaplastic large cell lymphoma-associated t(2;5) translocation in Hodgkin's disease.

Authors:  M Ladanyi; G Cavalchire; S W Morris; J Downing; D A Filippa
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

6.  Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.

Authors:  Keyvan Rezaï; François Lokiec; Isabelle Grandjean; Sophie Weill; Patricia de Cremoux; Vincent Bordier; Richard Ekue; Mickael Garcia; Marie-France Poupon; Didier Decaudin
Journal:  BMC Pharmacol       Date:  2007-10-27

Review 7.  The C-kit receptor-mediated signal transduction and tumor-related diseases.

Authors:  Jing Liang; Yan-Ling Wu; Bing-Jia Chen; Wen Zhang; Yoshimasa Tanaka; Hiroshi Sugiyama
Journal:  Int J Biol Sci       Date:  2013-05-08       Impact factor: 6.580

8.  Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease.

Authors:  D Re; C Wickenhauser; T Ahmadi; E Buchdunger; M Kochanek; V Diehl; J Wolf
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.